Skip to main content
OpenTrials
Completed

NCT Number: NCT01359774

31P-MRS and Huntington Disease

The purpose of this study is to identify and quantify a brain energy deficit in Huntington patients, using 31P-RMN spectroscopy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Huntington Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Chorea Cognition Disorders Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dementia Dyskinesias Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Mental Disorders Movement Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hopital de la Pitié-Salpetrière

Paris, 75013, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 5<UHDRS<50
  • Age>18 years
  • Ability to undergo MR scanning
  • Covered by french social security

Exclusion criteria

  • Evidence of psychiatric disorder
  • Attendant neurological disorder
  • Contraindications to MRI (claustrophobia, metallic or material implants)
  • Severe head injury
  • Unable to understand the protocol
  • Pregnancy
  • Failure to give informed consent
  • Subjects with exclusion criteria required by french law (e.g. subjects who require a legally authorized representative to obtain consent)
  • Unwillingness to be informed in case of abnormal MRI

Treatment and study plan

31P-MR spectroscopy

Other

Brain energy deficit is quantified using 31P-MR spectroscopy

31P-RMN spectroscopy

Other

Brain energy deficit is quantified using 31P-RMN spectroscopy

Primary outcomes

  1. Brain energy deficit in Huntington patients

    Time frame: one year

    31P-MRS allows quantification of high-energy phosphate metabolites such as ATP and phosphocreatine.

    Objective: to look at brain energy metabolism during rest and activation.

Secondary outcomes

  1. Correlating a brain energy deficit with (i) biochemical parameters and (ii) clinical parameters in Huntington patients

    Time frame: one year

    Biochemical parameters include metabolites that we previously showed to be biomarkers in HD: branched chain amino acids and IGF1.

    Clinical parameters include UHDRS and TFC.

Sponsors and collaborators

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Other Gov

Registry information

Official study title

31Phosphorus-Magnetic Resonance Spectroscopy and Huntington Disease

Acronym: PRO-MH

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
May 25, 2011
Registry last updated
Aug 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.